The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BUD, RBGLY and KPTI

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Anheuser-Busch Inbev Sa/Nv (NYSE: BUD)

Investors Affected : March 1, 2018 – October 24, 2018

A class action has commenced on behalf of certain shareholders in Anheuser-Busch Inbev Sa/Nv. According to the filed complaint, Defendants issued a steady stream of materially false and misleading reassurances about Anheuser Busch’s deleveraging efforts, cost cutting measures, EBITDA growth, the sufficiency of its liquidity and its debt maturity profile during the Class Period. These positive statements by Defendants created a false impression and materially misled investors about the Company’s finances, including the sustainability of Anheuser-Busch’s dividends. Once Defendants chose to speak about Anheuser-Busch’s finances, they had a duty to speak completely and truthfully, including speaking about those factors that were then having a material adverse effect on the Company’s deleveraging efforts.

Shareholders may find more information at https://securitiesclasslaw.com/securities/anheuser-busch-inbev-sa-nv-loss-submission-form/?id=2656&from=1

Reckitt Benckiser Group plc (OTCMKTS: RBGLY)

Investors Affected : On behalf of all purchasers of Reckitt American Depositary Shares (“ADSs”) from July 28, 2014 through April 9, 2019

A class action has commenced on behalf of certain shareholders in Reckitt Benckiser Group plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) defendants had engaged in a scheme to artificially inflate the sales of Suboxone Film by more than $3 billion by falsely touting the drug’s purportedly superior efficacy and safety as compared to tablets; (b) contrary to defendants’ public statements, the FDA and internal Company documents had concluded that Suboxone Film posed a potentially greater risk of abuse and child endangerment than other available treatments; (c) defendants had fabricated a safety scare involving Suboxone Tablets in order to unlawfully delay and prevent generic competition; (d) defendants had engaged in a massive marketing campaign that had misrepresented the purported benefits of Suboxone Film as compared to Suboxone Tablets to doctors, healthcare providers, government regulators and investors; (e) defendants had encouraged Suboxone sales through medical providers that they knew were overprescribing the drug, facilitating the drug’s abuse and/or prescribing it in a careless and clinically unwarranted manner, often to hundreds of individuals at a time; (f) as a result of (a)-(e) above, Reckitt’s revenues, net income an d earnings were artificially inflated and the product of illicit business practices; and (g) as a result of (a)-(f) above, Reckitt and Reckitt Pharma were exposed to extraordinary undisclosed legal and reputational risks that could result in billions of dollars in fines, lost business and legal judgments or other monetary penalties.

Shareholders may find more information at https://securitiesclasslaw.com/securities/reckitt-benckiser-group-plc-loss-submission-form/?id=2656&from=1

Karyopharm Therapeutics Inc (NASDAQGS: KPTI)

Investors Affected : on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.

A class action has commenced on behalf of certain shareholders in Karyopharm Therapeutics Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Shareholders may find more information at https://securitiesclasslaw.com/securities/karyopharm-therapeutics-inc-loss-submission-form/?id=2656&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 553851